INTERNATIONAL AIDS VACCINE INITIATIVE INC

EIN: 133870223 501(c)(3) International Affairs

NEW YORK, NY

Total Revenue
$129,678,400
Total Expenses
$132,896,237
Total Assets
$124,233,943
Net Assets
$63,923,752
🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Sign In — Free (10 views/day)

Financial Trends

Organization Details

Formation Year
1996
Legal Domicile
DE
Principal Officer
MARK B FEINBERG
Phone
2128471111
Tax Period
2023-01-01 to 2023-12-31

INTERNATIONAL AIDS VACCINE INITIATIVE INC, founded in 1996, is a major nonprofit in the International Affairs sector that reported $129.7M in total revenue in fiscal year 2023. Revenue decreased 12% compared to the prior year.

Mission

A NONPROFIT SCIENTIFIC RESEARCH ORGANIZATION THAT DEVELOPS VACCINES AND ANTIBODIES FOR HIV, TUBERCULOSIS, EMERGING INFECTIOUS DISEASES, AND NEGLECTED DISEASES.

Program Service Accomplishments

Program 1
Expenses: $112,549,400 Revenue: $2,297,276

RESEARCH AND DEVELOPMENT: THROUGH SCIENTIFIC AND CLINICAL RESEARCH IN AFRICA, INDIA, EUROPE, AND THE U.S., IAVI DEVELOPS VACCINES AND ANTIBODIES IN AND FOR THE DEVELOPING WORLD AND SEEKS TO...

Read more

RESEARCH AND DEVELOPMENT: THROUGH SCIENTIFIC AND CLINICAL RESEARCH IN AFRICA, INDIA, EUROPE, AND THE U.S., IAVI DEVELOPS VACCINES AND ANTIBODIES IN AND FOR THE DEVELOPING WORLD AND SEEKS TO ACCELERATE THEIR INTRODUCTION IN LOW-INCOME COUNTRIES. IAVI ADVANCES SCIENTIFIC DISCOVERY AND DEVELOPMENT BY FOSTERING UNIQUE COLLABORATIONS AMONG ACADEMIA, INDUSTRY, LOCAL COMMUNITIES, GOVERNMENTS, AND FUNDERS TO EXPLORE NEW AND BETTER WAYS TO ADDRESS PUBLIC HEALTH THREATS THAT DISPROPORTIONATELY AFFECT PEOPLE LIVING IN POVERTY. VACCINE AND ANTIBODY CANDIDATES ARE PUT THROUGH A RIGOROUS PROCESS OF CLINICAL EVALUATION AMONG KEY POPULATIONS TO ESTABLISH THEIR SAFETY AND EFFICACY, AN EFFORT THAT ENABLES IAVI TO STRENGTHEN THE HEALTHCARE INFRASTRUCTURE AND SCIENTIFIC CAPACITY OF COUNTRIES WHERE OUR CLINICAL PARTNERS OPERATE. TO DATE, IAVI AND ITS PARTNERS HAVE ADVANCED DOZENS OF HIV VACCINE CANDIDATES INTO EARLY STAGE CLINICAL TRIALS, INCLUDING A VACCINE THAT RECENTLY YIELDED PROMISING RESULTS AND IS PART OF AN EXCITING NEW APPROACH TO HIV VACCINE DESIGN. OTHER NOTABLE ACHIEVEMENTS INCLUDE THE FIRST HIV VACCINE TRIALS IN SUB-SAHARAN COUNTRIES, WHERE HIV BURDEN IS GREATEST, AND THE FIRST TRIAL OF AN MRNA HIV VACCINE CANDIDATE IN AFRICA. IAVI HAS CONDUCTED MORE THAN 50 EPIDEMIOLOGICAL STUDIES AND PROVIDED VOLUNTARY HIV TESTING, COUNSELING SERVICES, AND HEALTH CARE REFERRALS TO MORE THAN 870,000 INDIVIDUALS IN AFRICA. IAVI ALSO SUPPORTS PRECLINICAL DEVELOPMENT AND CLINICAL TESTING OF VACCINE CANDIDATES FOR OTHER DISEASES, INCLUDING TUBERCULOSIS, LASSA FEVER, MARBURG, EBOLA SUDEN, AND COVID-19, AS WELL AS ANTIBODY CANDIDATES FOR DISEASE PREVENTION AND TREATMENT. IAVI CONDUCTS TRIALS WITH THE HIGHEST SCIENTIFIC AND ETHICAL STANDARDS TO PROTECT THE RIGHTS, WELL-BEING, AND DIGNITY OF TRIAL VOLUNTEERS. IAVI HAS ALSO LAUNCHED RESEARCH CONSORTIA TO ADDRESS MAJOR SCIENTIFIC PROBLEMS OF BIOMEDICAL PRODUCT DEVELOPMENT. A SIGNIFICANT PORTION OF THE RESEARCH IAVI SUPPORTS IS CONDUCTED IN DEVELOPING COUNTRIES WHERE THE NEED FOR INFECTIOUS DISEASE PREVENTION IS GREATEST. IAVI ALSO SUPPORTS EXTERNAL RESEARCHERS BY PROVIDING TECHNICAL AND SCIENTIFIC EXPERTISE TO ACCELERATE THE DEVELOPMENT OF THEIR OWN PRODUCTS.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Sign In — Free (10 views/day)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $124,587,673
Program Service Revenue $2,297,276
Investment Income $2,762,423
Other Revenue $31,028
TOTAL REVENUE $129,678,400

Expense Breakdown

Grants Paid $31,255,891
Salaries & Benefits $48,531,593
Fundraising Expenses $258,570
Program Expenses $112,549,400
Other Expenses $53,108,753
TOTAL EXPENSES $132,896,237

Year-over-Year Comparison

2023 2022 Change
Revenue $129,678,400 $146,782,280 -0.1%
Expenses $132,896,237 $131,188,762 +0.0%
Net Income $-3,217,837 $15,593,518 -1.2%
Key Indicators
Grants to Organizations Grants to Individuals Lobbying Political Activity Foreign Activities Donor Advised Fund Schedule B Required
🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Sign In

Governance

Voting Members
14
Independent Members
13
Employees
268
Volunteers
13

Governance Policies

Conflict of Interest Policy
Whistleblower Policy
Document Retention Policy

Special Practices & Reported Activities

Operated a School
Operated a Hospital
Provided First Class Travel
Reported Conflict of Interest
Reported Asset Diversion
Excess Benefit Transaction
Made Political Expenditures
Engaged in Lobbying
Operated Donor Advised Fund
Maintained Art Collections
Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers
7
$2,429,431
Total Directors
14
$829,866
Key Employees
0
$0
Highest Compensated
5
reported
Name Title Hours/Week Role Reportable Comp Other Comp Total
MARK B FEINBERG PRESIDENT/CEO 35.00
Officer Director
$719,151 $110,715 $829,866
ERIC PAUL GOOSBY BOARD CHAIR 2.00
Officer Director
$0 $0 $0
ROBERT GOLDBERG BOARD TREASURER 2.00
Officer Director
$0 $0 $0
LINDA-GAIL BECKER BOARD MEMBER 1.00
Director
$0 $0 $0
DAVID BLUMBERG BOARD MEMBER 1.00
Director
$0 $0 $0
JIM CONNOLLY BOARD MEMBER 1.00
Director
$0 $0 $0
MARK DYBUL BOARD MEMBER 1.00
Director
$0 $0 $0
WAFAA EL-SADR BOARD MEMBER 1.00
Director
$0 $0 $0
ALEXIS M PINTO BOARD MEMBER 1.00
Director
$0 $0 $0
JOHN W SHIVER BOARD MEMBER 1.00
Director
$0 $0 $0
SUSAN SILBERMANN BOARD MEMBER 1.00
Director
$0 $0 $0
ANNE MARTIN SIMONDS BOARD MEMBER 1.00
Director
$0 $0 $0
RAJEEV VENKAYYA BOARD MEMBER 1.00
Director
$0 $0 $0
MARIJKE WIJNROKS BOARD MEMBER 1.00
Director
$0 $0 $0
ANA CESPEDES MONTOYA CHIEF OPERATING OFFICER 35.00
Officer
$531,087 $79,268 $610,355
LOUIS D SCHWARTZ ASST. SEC. & CFAO 35.00
Officer
$390,586 $76,520 $467,106
MIN DING GEN. COUNS. & SEC. 35.00
Officer
$333,986 $71,843 $405,829
MARIO GAGLIANO CPO, VP OF HR (FROM 9/23) 35.00
Officer
$102,045 $14,230 $116,275
SWATI GUPTA VP, HEAD OF EID & EPIDEM. 35.00
Highest
$379,201 $76,490 $455,691
DAGNA LAUFER VP & HEAD OF CLINICAL DEV. 35.00
Highest
$394,188 $41,148 $435,336
CHRISTOPHER PARKS - ASSOC AVP. VIRAL VAC. & HEAD OF DDL 35.00
Highest
$365,204 $62,119 $427,323
ERIC SKJEVELAND VP, BUSINESS DEVELOPMENT 35.00
Highest
$341,395 $36,715 $378,110
SANGEETHA SAGAR VP & HEAD OF PRODUCT DEV 35.00
Highest
$376,047 $33,504 $409,551
FRANCES SINHA FORMER OFFICER 35.00
$105,000 $0 $105,000
Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year Revenue Expenses Assets Net Income
2024 No data No data No data No data
2023 $129,678,400 $132,896,237 $124,233,943 $-3,217,837
2022 $146,782,280 $131,188,762 $128,948,484 $15,593,518
2021 $126,352,598 $113,151,683 $107,049,023 $13,200,915
2020 $97,111,665 $96,068,184 $81,721,759 $1,043,481
2019 $88,458,944 $87,783,507 $74,755,062 $675,437
2018 $77,192,773 $83,383,050 $83,382,669 $-6,190,277
Explore More Nonprofits
Top 100 Nonprofits in New York Largest U.S. Nonprofits Best Rated Nonprofits Most Efficient Nonprofits

Compare INTERNATIONAL AIDS VACCINE INITIATIVE INC with other nonprofits in New York and across the country.